High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors - Takeaways - MDSpire

High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors

  • By

  • Junichi Hara

  • Kimikazu Matsumoto

  • Naoko Maeda

  • Mariko Takahara-Matsubara

  • Saori Sugimoto

  • Hiroaki Goto

  • November 3, 2022

  • 0 min

Share

  • 1

    Thiotepa is an antitumor alkylating agent used as high-dose chemotherapy before autologous HSCT for pediatric solid tumors.

  • 2

    The drug effectively crosses the blood-brain barrier, achieving high concentrations in the cerebrospinal fluid.

  • 3

    A recent study showed high survival rates of 77.8% for pediatric solid tumors and 100% for malignant lymphoma with thiotepa.

  • 4

    Thiotepa was approved in Japan for use as HDT before autologous HSCT for pediatric malignant solid tumors in 2019.

  • 5

    The expanded access program evaluated thiotepa's safety and efficacy in pediatric patients with solid tumors or brain tumors.

Original Source(s)

High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors

  • by Junichi Hara, Kimikazu Matsumoto, Naoko Maeda, Mariko Takahara-Matsubara, Saori Sugimoto, Hiroaki Goto

  • November 3, 2022

Related Content

Clinical and imaging manifestations of intracerebral hemorrhage in brain tumors and metastatic lesions: a comprehensive overview

Influence of postoperative D-dimer evaluation and intraoperative use of intermittent pneumatic vein compression (IPC) on detection and development of perioperative venous thromboembolism in brain tumor surgery

Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series